期刊文献+

卵巢上皮性癌复发的相关因素研究 被引量:12

原文传递
导出
摘要 目的:探讨影响卵巢上皮性癌复发的影响因素。方法:回顾性分析经病理检验证实的143例卵巢上皮性癌患者的病例及随访资料,对影响复发的因素分别进行单因素及多因素分析。结果:临床分期、残瘤灶大小、病理类型、组织分化、术前及化疗3个疗程结束后的CA125水平是影响卵巢上皮性癌复发的独立相关因素(P<0.05)。结论:卵巢上皮性癌的复发是多因素综合作用的结果。临床分期晚、残瘤灶直径大、透明细胞癌或未分化的腺癌、组织分化低、术前及化疗3个疗程结束时的CA125水平高,是卵巢癌上皮性癌复发危险因素。
作者 刘宝莲 韩萍
出处 《中国妇幼保健》 CAS 北大核心 2013年第20期3250-3254,共5页 Maternal and Child Health Care of China
  • 相关文献

参考文献7

  • 1王新宇,叶菁,冯素文,吕卫国,万小云,谢幸.血清CA125水平测定在预测卵巢上皮性癌复发和预后中的价值[J].中华妇产科杂志,2010,45(11):813-816. 被引量:28
  • 2Quan - Qing Zheng, Ping Wang, Rong Hui, et al. Prognostic analysis of ovarian cancer patients using the Cox regression model [J] . Chinese Journal Cancer, 2009, 28 (2): 170.
  • 3HanByoul C, Hye WH, Sang WK, et al. Pre - treatment neu- trophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment [J] . Cancer Im- munol Immunother, 2009, 58: 15.
  • 4Menon U, Gentry - Maharaj A, Hallett R, et al. Sensitivity and specicity of muhimodal and ultrasound screening for ovari- an cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovari- an Cancer Screening (UKCTOCS) [J] . Lancet Oncol, 2009, 10: 327.
  • 5Hee SK, Noh - Hyun P, Hyun HC, et al. Are three additional cycles of chemotherapy useful in patients with advanced - stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin[J] ? Jpn J Clin Oncol, 2008, 38 (6) : 445.
  • 6Ayhan A, Celik H, Taskiran C, et al. Oncologic and repro- ductive outcome after fertility - saving surgery in ovarian cancer[J] . Eur J Gynaecol Oncol, 2003, 24 : 223.
  • 7许沈华,应莉莎,朱赤红,谢锦波.卵巢浆液性腺癌患者生存因素分析[J].临床与实验病理学杂志,2011,27(2):142-145. 被引量:4

二级参考文献28

共引文献29

同被引文献110

  • 1韦佩佳.老年复发卵巢癌患者预后影响因素[J].中国老年学杂志,2014,34(8):2081-2082. 被引量:10
  • 2周珅,杨建玲,王耀华.ATP-TCA检测食管癌化学治疗药物的体外敏感性研究[J].中国医药导刊,2013,15(S1):148-149. 被引量:1
  • 3林莉,刘晓晴,宋三泰.DNA损伤修复与铂类耐药研究进展[J].中国肿瘤,2006,15(1):29-31. 被引量:29
  • 4Ushijima K. Treatment for recurrent ovarian cancer-at first re- lapse[J]. J Oncol, 2010,2010 : 497-429.
  • 5Naumann RW, Coleman RL. Management strategies for recur- rent platinum-resistant oarian cancerOUS. Drugs,2011,71(11) : 1397-1412.
  • 6Bristow RE, Pnri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a recta-analysis [J]. Gynecol Oncol, 2009, 112(1) : 265-274.
  • 7Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma[J]. Cancer,2000,88(1) : 144-153.
  • 8Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort[J]. Br J Cancer,2011,105(7): 890-896.
  • 9Lee CK, Simes RJ, Brown C, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recur- rent ovarian cancer[J]. AnnOncol,2012, 24(4):937- 943.
  • 10Previs RA, Bevis KS, Huh W, et al. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy[J]. Gynecol Oncol, 2014,132 (3) : 531-536.

引证文献12

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部